These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30932883)

  • 21. Umbilical Cord Blood-Derived M1 Macrophage Exosomes Loaded with Cisplatin Target Ovarian Cancer
    Zhang X; Wang J; Liu N; Wu W; Li H; Lu W; Guo X
    Mol Pharm; 2023 Nov; 20(11):5440-5453. PubMed ID: 37819754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis.
    Li C; Wang Q; Luo Y; Xiang J
    Anal Cell Pathol (Amst); 2022; 2022():5632164. PubMed ID: 36247876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
    Zou W; Ma X; Hua W; Chen B; Cai G
    Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABT‑737 increases cisplatin sensitivity through the ROS‑ASK1‑JNK MAPK signaling axis in human ovarian cancer cisplatin‑resistant A2780/DDP cells.
    Li X; Guo Y; Xing Z; Gong T; Yang L; Yang T; Chang B; Wang X; Yu B; Guo R
    Oncol Rep; 2024 Sep; 52(3):. PubMed ID: 39054955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells.
    Zhao WJ; Deng BY; Wang XM; Miao Y; Wang JN
    Asian Pac J Cancer Prev; 2015; 16(6):2453-8. PubMed ID: 25824780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression.
    Sun LM; Liu YC; Li W; Liu S; Liu HX; Li LW; Ma R
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1198-1205. PubMed ID: 28387913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells.
    Wang Z; Xie Y; Wang H
    Cancer Biol Ther; 2005 Jul; 4(7):716-9. PubMed ID: 15970709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.
    Zhang Y; Yu JJ; Tian Y; Li ZZ; Zhang CY; Zhang SF; Cao LQ; Zhang Y; Qian CY; Zhang W; Zhou HH; Yin JY; Liu ZQ
    Oncotarget; 2015 Sep; 6(28):25441-51. PubMed ID: 26213845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
    Li S; Yi Z; Li M; Zhu Z
    J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long non-coding RNA HOXA11-AS knockout inhibits proliferation and overcomes drug resistance in ovarian cancer.
    Chen Y; Cui Z; Wu Q; Wang H; Xia H; Sun Y
    Bioengineered; 2022 May; 13(5):13893-13905. PubMed ID: 35706412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interference with SMO increases chemotherapy drug sensitivity of A2780/DDP cells by inhibiting the Hh/Gli signaling pathway.
    Ma S; Liu D; Tan W; Du B; Liu W; Li W; Jiao Y
    J Cell Biochem; 2020 Jun; 121(5-6):3256-3265. PubMed ID: 31904145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
    Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
    Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
    Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.